Engineers Gate Manager LP Denali Therapeutics Inc. Transaction History

Engineers Gate Manager LP

16 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	SELL	$14.96 - $23.22 $302,580 - $469,647	-20,226 Reduced 64.5%	11,130 $258,000
Q1 2024 May 15, 2024	BUY	$15.83 - $23.35 $295,767 - $436,271	18,684 Added 147.44%	31,356 $643,000
Q4 2023 Feb 14, 2024	SELL	$16.2 - $23.18 $177,179 - $253,519	-10,937 Reduced 46.33%	12,672 $271,000
Q3 2023 Nov 14, 2023	SELL	$20.63 - $30.17 $169,392 - $247,725	-8,211 Reduced 25.8%	23,609 $487,000
Q2 2023 Aug 14, 2023	SELL	$23.37 - $32.96 $583,432 - $822,846	-24,965 Reduced 43.96%	31,820 $939,000
Q1 2023 May 15, 2023	BUY	$21.91 - $32.67 $1.24 Million - $1.86 Million	56,785 New	56,785 $1.31 Million
Q2 2022 Aug 15, 2022	BUY	$20.88 - $35.19 $26,601 - $44,832	1,274 Added 7.94%	17,320 $510,000
Q1 2022 May 16, 2022	BUY	$29.0 - $47.27 $300,324 - $489,528	10,356 Added 182.0%	16,046 $516,000
Q4 2021 Feb 14, 2022	BUY	$42.59 - $55.02 $242,337 - $313,063	5,690 New	5,690 $254,000
Q3 2021 Nov 15, 2021	SELL	$48.48 - $78.23 $292,334 - $471,726	-6,030 Closed	0 $0
Q2 2021 Aug 16, 2021	SELL	$50.3 - $78.44 $430,065 - $670,662	-8,550 Reduced 58.64%	6,030 $473,000
Q1 2021 May 17, 2021	BUY	$53.8 - $81.53 $505,720 - $766,382	9,400 Added 181.47%	14,580 $833,000
Q4 2020 Feb 16, 2021	SELL	$36.89 - $93.56 $106,095 - $269,078	-2,876 Reduced 35.7%	5,180 $434,000
Q3 2020 Nov 16, 2020	BUY	$23.13 - $38.84 $186,335 - $312,895	8,056 New	8,056 $289,000
Q1 2020 May 15, 2020	SELL	$14.2 - $27.98 $181,660 - $357,948	-12,793 Closed	0 $0
Q4 2019 Feb 14, 2020	BUY	$14.4 - $19.99 $184,219 - $255,732	12,793 New	12,793 $223,000

227

119M

60.6K

48.4K

Ticker DNLI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 134,174,000
Market Cap $2.88B
Description
Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151, a small molecule inhibitor, which is in phase I and phase Ib clinical trials for the treatm...

Get notified when there are updates to the investment portfolio of Engineers Gate Manager LP, based on Form 13F filings with the SEC.

Stay updated on Engineers Gate Manager LP with notifications on news.